← Back to contracts

New Generation of Glucose Control Technologies Incorporating AI/ML Tools/Strategies (R01 - Clinical Trial Optional)

US · US National Institutes of Health (NIH) grant open #RFA-DK-27-146
Response due Jun 17, 2026 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting R01 research grant applications focused on developing a new generation of glucose control technologies that incorporate artificial intelligence and machine learning (AI/ML) tools and strategies. This is a funding opportunity announcement (FOA) under the RFA-DK-27-146 number, managed by NIH's diabetes/kidney research portfolio. Clinical trials are optional under this mechanism. The opportunity is open from May 7, 2026 through June 17, 2026.

What they want

Applicants must propose research aimed at advancing glucose control technologies through the integration of AI/ML tools and strategies. The R01 mechanism supports discrete, specified, circumscribed projects conducted by named investigators in established research areas. Clinical trials may be optionally included. Specific deliverables, milestones, and technical requirements are governed by NIH standard R01 grant terms and conditions.
Technical requirements
  • Integration of AI/ML tools and strategies into glucose control technologies
  • R01 grant mechanism compliance
  • Clinical trial protocol compliance if clinical trial is included
  • NIH standard terms and conditions for R01 awards

How they evaluate

  • Scientific and technical merit (as evaluated by NIH peer review/study section)
  • Significance and innovation
  • Investigator qualifications and environment
  • Approach and methodology
  • Protection of human subjects (if clinical trial included)
Submission: Electronic submission via Grants.gov and NIH eRA Commons

Eligibility & certifications

SAM.gov registration (for institutional applicants)NIH eRA Commons registrationCompliance with NIH human subjects and clinical trial policies if applicable

Risks & flags

  • Funding opportunity announcement (FOA) number RFA-DK-27-146 suggests a targeted/directed research topic, which may favor research groups with existing NIH diabetes/kidney program relationships
  • Short response window of approximately 41 days from open to close date
  • Highly specific scope (AI/ML + glucose control) may advantage labs with pre-existing NIH-funded diabetes technology programs

Market context

inferred from NAICS
Professional, Scientific & Technical Services
NAICS 541711
US market size
$2.0T
Typical award
$25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

New Generation of Glucose Control Technolo…
Due Jun 17
Onboard ↗